Clinical Trial of Trelagliptin Succinate Tablets in the Treatment of Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 254 participants.
Also called NCT03940183
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 254 participants
- Registry
-
NCT03940183
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT03940183. Randomized; quadruple masking; primary purpose treatment. Start 2019-07-08 (actual); primary completion 2020-12-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Clinical Trial of Trelagliptin Succinate Tablets in the Treatment of Type 2 Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Trelagliptin Succinate
- Intervention (Drug)
- Placebo Oral Tablet
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Record details
- Record id
cardio:ct-nct03940183- Content hash
444bb2da20a75a8e6861e59d4ae2797dd63db1d3ae0a9fdf5f47cd88633eb3d2